杂交冠状动脉血运重建技术治疗冠状动脉粥样硬化性心脏病研究进展  

Research progress of hybrid coronary revascularization in treating coronary atherosclerotic heart disease

作　　者：张晓宇 潘媛媛[2] 付明欢 林赟[2] 陈怡然 彭羽[2] ZHANG Xiaoyu;PAN Yuanyuan;FU Minghuan;LIN Yun;CHEN Yiran;PENG Yu(School of Medicine of Univer-sity of Electronic Science and Technology of China,Chengdu 610054,Sichuan,China;不详)

机构地区：[1]电子科技大学医学院,四川成都610054 [2]四川省医学科学院·四川省人民医院(电子科技大学附属医院),四川成都610072 [3]广东省广州市疾病预防控制中心,广东广州510440

出　　处：《实用医学杂志》2025年第6期916-920,共5页The Journal of Practical Medicine

基　　金：国家自然科学基金青年项目(编号:32100082);四川省科技计划重点研发项目(编号:2022YFS0154)。

摘　　要：冠状动脉粥样硬化性心脏病(冠心病)在我国发病率较高,临床多给予药物治疗、经皮冠状动脉介入术、冠状动脉旁路移植术等。微创介入治疗为冠状动脉多支狭窄患者首选,但多支血管病变合并其他疾病患者多推荐冠状动脉旁路移植术。然而,经皮冠状动脉介入术存在血管再狭窄、血栓等事件风险,杂交冠状动脉血运重建术随之诞生。基于此,该文主要对冠心病进行介绍,就杂交冠状动脉血运重建术优势、应用、对患者的选择等作一综述。The incidence rate of coronary atherosclerotic heart disease(commonly referred to as coronary heart disease)remains high in China.In clinical practice,drug therapy,percutaneous coronary intervention(PCI),and coronary artery bypass grafting(CABG)are commonly employed.For patients with multi-vessel coronary artery stenosis,minimally invasive interventional therapy is often the preferred option.However,for those with multi-vessel disease complicated by comorbidities,CABG is generally recommended.Despite its advantages,PCI carries risks such as vascular restenosis,thrombosis,and other adverse events.Consequently,hybrid coronary revascularization(HCR)has emerged as an alternative approach.This paper provides an overview of coronary heart disease and reviews the advantages,applications,and patient selection criteria for HCR.

关 键 词：杂交冠状动脉血运重建技术 冠状动脉粥样硬化性心脏病 经皮冠状动脉介入术 冠状动脉旁路移植术 进展 

分 类 号：R654.2[医药卫生—外科学]